Hidradenitis Suppurativa Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed dermatology and immunology journals, clinical trial repositories, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), ClinicalTrials.gov, American Academy of Dermatology (AAD), European Academy of Dermatology and Venereology (EADV), Hidradenitis Suppurativa Foundation (HSF), International Hidradenitis Suppurativa Foundation (IHSF), Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, World Health Organization (WHO) Global Health Observatory, EU Eurostat Health Database, American College of Surgeons (ACS), National Institute for Health and Care Excellence (NICE) guidelines, and national health ministry reports from key markets. These sources were used to collect epidemiological prevalence data, regulatory approval timelines for TNF-α inhibitors and IL-17/IL-23 inhibitors, clinical safety and efficacy studies (HiSCR endpoints), pipeline development tracking, and treatment algorithm evolution across mild, moderate, and severe HS disease stages.

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research phase. CEOs, VPs of Immunology & Dermatology Franchise, directors of regulatory affairs, directors of market access, and clinical development leaders from biopharmaceutical companies creating biologic and small-molecule treatments for HS were examples of supply-side sources. Demand-side sources included medical directors of academic medical centers, procurement leads from specialty dermatology clinics and infusion centers, board-certified dermatologists (especially those with expertise in inflammatory and acneiform disorders), general surgeons with expertise in dermatologic surgery, wound care specialists, and formulary decision-makers from hospital systems. Primary research confirmed pipeline candidate timelines (Phase II/III readouts), validated market segmentation across treatment modalities (biologics vs. surgical vs. conventional), and collected data on clinical adoption barriers, biologic therapy reimbursement dynamics, off-label usage patterns for unapproved biologics, and patient journey mapping from diagnosis to treatment initiation.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (40%), Director Level (30%), Others (30%)

• By Region: North America (38%), Europe (30%), Asia-Pacific (25%), Rest of World (7%)

Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure volume assessment. The methodology included:

• Identification of 35+ key biopharmaceutical manufacturers and medical device companies across North America, Europe, Asia-Pacific, and Latin America developing HS-specific or dermatology/immunology crossover therapies

• Product mapping across TNF-α inhibitors (adalimumab, infliximab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), IL-1 inhibitors, JAK inhibitors, antibiotic therapies, and surgical intervention categories (wide excision, laser therapy, deroofing procedures)

• Analysis of reported and modeled annual revenues specific to HS indications, including off-label usage attribution for biologics approved for psoriasis and Crohn's disease

• Coverage of manufacturers representing 75-80% of global biologic therapy market share and 60-65% of surgical device market share in 2024

• Extrapolation using bottom-up (patient prevalence × diagnosis rate × treatment penetration × ASP by country/region) and top-down (manufacturer revenue validation and prescription data triangulation) approaches to derive segment-specific valuations across biologics, small molecules, and surgical treatment modalities

Key Adjustments Made:

Secondary Sources: Replaced aesthetic/cosmetic sources (ISAPS, ASDS, ASPS) with HS-specific dermatology and immunology authorities (AAD, EADV, HSF, IHSF) and surgical societies (ACS)

Primary Breakdown: Modified percentages across all categories (Company Tier, Designation, and Region) as requested

Market Estimation: Adjusted from dermal filler categories (HA, CaHA, PLLA) to HS treatment categories (biologics by mechanism of action, surgical interventions, conventional therapies) and changed revenue tiers appropriate for biopharma vs. aesthetics companies